Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy

Abstract Background Prostate cancer remains a significant health challenge, as conventional treatments often fail to provide long-term benefits in the advanced stages. This study explored the potential of mRNA vaccines as novel therapeutic strategies, specifically focusing on the combination of 5T4...

Full description

Saved in:
Bibliographic Details
Main Authors: Fei Cao, Yuandong Xu, Yupeng Guan, Kexin Zhang, Haowei Qiu, Zhen Xu, Yunru He, Ze Xiu Xiao, Gao-feng Zha, Jun Pang
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Journal of Nanobiotechnology
Online Access:https://doi.org/10.1186/s12951-025-03607-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849235045807554560
author Fei Cao
Yuandong Xu
Yupeng Guan
Kexin Zhang
Haowei Qiu
Zhen Xu
Yunru He
Ze Xiu Xiao
Gao-feng Zha
Jun Pang
author_facet Fei Cao
Yuandong Xu
Yupeng Guan
Kexin Zhang
Haowei Qiu
Zhen Xu
Yunru He
Ze Xiu Xiao
Gao-feng Zha
Jun Pang
author_sort Fei Cao
collection DOAJ
description Abstract Background Prostate cancer remains a significant health challenge, as conventional treatments often fail to provide long-term benefits in the advanced stages. This study explored the potential of mRNA vaccines as novel therapeutic strategies, specifically focusing on the combination of 5T4 and CD70 mRNA delivered via lipid nanoparticles (LNPs). 5T4, which is highly expressed in various tumors but minimally expressed in normal tissues, is an ideal target for immunotherapy. CD70 was selected for its capacity to enhance T cell activation and augment the overall immune response. Results Our findings demonstrated that the combination of 5T4 and CD70 mRNA-LNPs significantly enhanced both humoral and cellular immunity, resulting in improved tumor suppression and prolonged survival in a prostate cancer mouse model. Mechanistically, these LNPs increased the immune responses, including elevated 5T4-specific antibodies, enhanced CD8 + T cell activity, and more active natural killer (NK) cells. Conclusions These results suggest that this combined mRNA vaccine strategy may offer more effective and durable treatments for prostate cancer and that CD70 mRNA, as an immune activator, has broader potential for cancer immunotherapy. Graphical Abstract
format Article
id doaj-art-06597f58328745909b2f6c686f4c0a49
institution Kabale University
issn 1477-3155
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series Journal of Nanobiotechnology
spelling doaj-art-06597f58328745909b2f6c686f4c0a492025-08-20T04:02:55ZengBMCJournal of Nanobiotechnology1477-31552025-07-0123112010.1186/s12951-025-03607-4Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapyFei Cao0Yuandong Xu1Yupeng Guan2Kexin Zhang3Haowei Qiu4Zhen Xu5Yunru He6Ze Xiu Xiao7Gao-feng Zha8Jun Pang9Department of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen UniversityDepartment of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen UniversityDepartment of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen UniversityResearch and development center, Shenzhen MagicRNA BiotechScientific Research Center, the Seventh Affiliated Hospital, Sun Yat-sen UniversityDepartment of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen UniversityScientific Research Center, the Seventh Affiliated Hospital, Sun Yat-sen UniversityResearch and development center, Shenzhen MagicRNA BiotechScientific Research Center, the Seventh Affiliated Hospital, Sun Yat-sen UniversityDepartment of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen UniversityAbstract Background Prostate cancer remains a significant health challenge, as conventional treatments often fail to provide long-term benefits in the advanced stages. This study explored the potential of mRNA vaccines as novel therapeutic strategies, specifically focusing on the combination of 5T4 and CD70 mRNA delivered via lipid nanoparticles (LNPs). 5T4, which is highly expressed in various tumors but minimally expressed in normal tissues, is an ideal target for immunotherapy. CD70 was selected for its capacity to enhance T cell activation and augment the overall immune response. Results Our findings demonstrated that the combination of 5T4 and CD70 mRNA-LNPs significantly enhanced both humoral and cellular immunity, resulting in improved tumor suppression and prolonged survival in a prostate cancer mouse model. Mechanistically, these LNPs increased the immune responses, including elevated 5T4-specific antibodies, enhanced CD8 + T cell activity, and more active natural killer (NK) cells. Conclusions These results suggest that this combined mRNA vaccine strategy may offer more effective and durable treatments for prostate cancer and that CD70 mRNA, as an immune activator, has broader potential for cancer immunotherapy. Graphical Abstracthttps://doi.org/10.1186/s12951-025-03607-4
spellingShingle Fei Cao
Yuandong Xu
Yupeng Guan
Kexin Zhang
Haowei Qiu
Zhen Xu
Yunru He
Ze Xiu Xiao
Gao-feng Zha
Jun Pang
Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy
Journal of Nanobiotechnology
title Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy
title_full Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy
title_fullStr Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy
title_full_unstemmed Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy
title_short Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy
title_sort enhancing the potency of 5t4 mrna vaccine by cd70 mrna lnps through adcc and t cell boosting in prostate cancer therapy
url https://doi.org/10.1186/s12951-025-03607-4
work_keys_str_mv AT feicao enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT yuandongxu enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT yupengguan enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT kexinzhang enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT haoweiqiu enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT zhenxu enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT yunruhe enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT zexiuxiao enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT gaofengzha enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy
AT junpang enhancingthepotencyof5t4mrnavaccinebycd70mrnalnpsthroughadccandtcellboostinginprostatecancertherapy